First Drug Approved for Rare Eye Cancer.

Tebentafusp, the first drug shown to extend overall survival in people with uveal melanoma, was greenlighted by the FDA in late January to treat patients with inoperable or metastatic forms of the aggressive eye cancer. The drug is also the first T-cell receptor therapy to reach the market. ©2022 American Association for Cancer Research.